Process for preparation of asciminib
The described process effectively reduces impurity levels in Asciminib production by using specific catalysts and purification methods, ensuring high yield and purity for industrial-scale Asciminib production.
Patent Information
- Application Number
- PCT/EP2026/063328
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
The existing process for preparing Asciminib results in high impurity levels, making purification difficult and inefficient, and is not cost-effective for industrial-scale production.
A process involving the reaction of compound (2) with compound (3) using specific catalysts in the presence of solvents and bases, followed by crystallization and deprotection steps to achieve high purity Asciminib, reducing impurity levels to less than 3%.
The process achieves high yield and purity of Asciminib, with impurity levels below 3%, suitable for industrial application and pharmaceutical formulation.
Smart Images

Figure EP2026063328_12112026_PF_FP_ABST
Abstract
Description
[0001] P1829PC00
[0002] PROCESS FOR PREPARATION OF ASCIMINIB BACKGROUND OF THE PRESENT INVENTION
[0003] The present invention relates to a process for preparation of Asciminib, the compound of formula (I) or a salt or a cocrystal or a solvate thereof.
[0004] Asciminib, N-[4-[Chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-l-yl]-5-(lH-pyrazol-5-yl)pyridine-3-carboxamide of the formula (1):
[0005]
[0006] (1)
[0007] is an allosteric inhibitor of BCR-ABL kinase.
[0008] Asciminib was registered in form of HC1 salt for treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with two or more tyrosine kinase inhibitors and adult patients with Ph+ CML in chronic phase with the T3151 mutation.
[0009] Asciminib was first disclosed in WO2013171639 application. The process for preparation of Asciminib described in WO2013171639 is depicted in following scheme:
[0010] (2)
[0011]
[0012] AsciminibWhen the process described in WO2013171639 is used the compound of formula (4) contains high amount of impurity (Imp) (the ratio between compound of formula (4) and impurity (Imp) is approximately 1:1). Purification of compound of formula (4) to remove Impurity (Imp) is difficult:
[0013]
[0014] (Imp)
[0015] Hence, there is a need for an improved process for preparing Asciminib.
[0016] In particular, it would be desirable to have a process that is efficient in terms of yield and chemical purity, cost effective in terms of reagents and reaction conditions, and which is applicable on an industrial scale.
[0017] BRIEF DESCRIPTION OF THE PRESENT INVENTION
[0018] The presented invention relates to a process for preparation of Asciminib, compound of formula (1), or a salt or a cocrystal or a solvate thereof,
[0019]
[0020] (1)
[0021] the process comprising:a. Reacting compound of formula (2) with compound of formula (3):
[0022] 'B
[0023] d
[0024]
[0025] (3)
[0026] Hal: halogen Prot: Protective group .
[0027] a compound of general formula Pd(Hali)2AnAr2;
[0028] Ari is imidazolidine or 2,3 -dihydro- IH-imidazole subtituted on N atoms with 1 or 2 Ar3
[0029] Ar2 is pyridine group that is subtituted with 1 or 2 Hah group
[0030] Ar3is a phenyl group that can be substituted by 1 or 2 or 3 Alki
[0031] Alki is straight or branched alkyl group or alkyl aryl group
[0032] Hah is selected from Cl or Br
[0033] or
[0034] a compound of general formula Pd(Hah)(r|3-allyl)Ar5
[0035] A is 2,3-dihydro-lH-imidazole subtituted on N atom with 1 or 2 Ar3
[0036] Ar3is a phenyl group that can be substituted with 1 or 2 or 3 Alki
[0037] Alki is straight or branched alkyl group or alkyl aryl group
[0038] Hah is selected from Cl or Br
[0039] to provide compound of formula (4):
[0040] N-N
[0041] N
[0042] N‘
[0043]
[0044] b. Transforming compound of formula (4) into compound of formula (1) or a salt or a cocrystal or a solvate thereof.
[0045] DETAILED DESCRIPTION OF THE PRESENT INVENTION
[0046] The presented invention relates to a process for preparation of Asciminib, compound of formula (1), or a salt or a cocrystal or a solvate thereof:
[0047]
[0048] the process comprising:
[0049] a. Reacting compound of formula (2) with compound of formula (3):
[0050] Prot
[0051] XN-N
[0052] ...OH
[0053] (3)
[0054]
[0055] Prot: Protective group .
[0056] in a presence of a catalyst selected from:
[0057] a compound of general formula Pd(Hah)2AriAr2
[0058] Ari is imidazolidine or 2,3 -dihydro- IH-imidazole subtituted on N atoms with 1 or 2 Ar3
[0059] Ar2 is pyridine group that is subtituted with 1 or 2 Hah group
[0060] Ar3is a phenyl group that can be substituted by 1 or 2 or 3 Alki
[0061] Alki is straight or branched alkyl group or alkyl aryl group
[0062] Hah is selected from Cl or Br
[0063] ora compound of general formula Pd(Hali)(r|3-allyl)Ar5
[0064] Ar 5 is 2,3-dihydro-lH-imidazole subtituted on N atom with 1 or 2 An Ars is a phenyl group that can be substituted with 1 or 2 or 3 Alki
[0065] Alki is straight or branched alkyl group or alkyl aryl group
[0066] Hah is selected from Cl or Br
[0067] to provide compound of formula (4):
[0068]
[0069] b. Transforming compound of formula (4) into compound of formula (1) or a salt or a cocrystal or a solvate thereof.
[0070] In the catalyst of general formula Pd(Hah)2AriAr2, Hah is preferably Cl, Alklis straight or branched alkyl group or alkyl aryl group preferably selected from methyl or ethyl or propyl or isopropyl or butyl or isobutyl or heptyl or hexyl or 4-methyl heptyl or diphenyl methyl. Alki is preferably isopropyl.
[0071] In the catalyst of general formula Pd(Hah)(r|3-allyl)Ar5, Hah is preferably Cl, Alki is straight or branched alkyl group or alkyl aryl group preferably selected from methyl or ethyl or propyl or isopropyl or butyl or isobutyl or heptyl or hexyl or 4-methyl heptyl or diphenyl methyl. Alki is preferably isopropyl.
[0072] The catalyst are more preferably selected from:
[0073]
[0074] i-Pr means isopropyl.
[0075] Hal in compound of formula (2) can be selected from Cl, Br or I, preferably it is Br. Prot in compound of formula (3) or compound of formula (4) can be selected from tetrahydro-2H-pyran-yl or (benzyloxy) carbonyl (Cbz) or (tert-butoxy) carbonyl (Boc) or benzyl (Bz) or 4-methoxybenzyl (PMB) or ((2-trimethylsilyl)ethoxy)-methyl preferably is it tetrahy dro-2H-pyran-yl .
[0076] The molar ration between compound of formula (2) and the catalyst can be between 0.003:1 and 0.006:1.
[0077] The molar ratio between compound of formula (2) and the compound of formula (3) can be between 1:1.2 and 1 :2.5, preferably it is between 1:1.4 and 1:2.1.
[0078] The reaction step a. can be done in a solvent. The solvent can be selected from tetrahydrofuran or toluene or 2-methyl tetrahydrofuran or dioxane or dimethoxy ethane or water or a combination thereof. The solvent is preferably selected form tetrahydrofuran or tetrahydrofuran in combination with water. The concentration of compound of formula (2) in the solvent can be between 0.09 g / ml and 0.22 g / ml. The concentration of compound of formula (3) in the solvent can be between 0.05 g / ml and 0.17 g / ml.
[0079] The reaction step a. can be done in a presence of a base. The base can be selected from a carbonate such as sodium carbonate or potassium carbonate or cesium carbonate or a phosphate such as potassium phosphate or sodium phosphate. The molar ratio between the base and the compound of formula (2) can be between 1.8:1 and 2.2:1, preferably it is 2: 1. The concentration of the base in the solvent can be between 0.05 g / ml and 0.11 g / ml.
[0080] Compound of formula (2) is mixed with compound of formula (3), the base and the solvent. Obtained mixture can be optionally degassed for example by vacuum or by using argon or by use of combination thereof. To the mixture the catalyst is added. The mixture is stirred at a temperature between 60°C and 85°C for between 1 and 5 hours. The reactionprogress can be monitored by a suitable analytical technique, e.g. by HPLC or GC. After the reaction is finished, to the reaction mixture a mixture of an acetate such as isopropyl acetate or ethyl acetate and aqueous sodium carbonate solution, for example 5% solution, is added. The volume ratio between the acetate and aqueous sodium carbonate solution can be for example 2:1. The mixture is then stirred for between 15 and 60 minutes. The mixture can be optionally filtered off, the phases are separated and the organic phase can be washed, for example with brine. After phase separation, the organic phase is concentrated in vacuo to provide compound of formula (4).
[0081] The compound of formula (4) can be crystallized form a mixture of tetrahydrofuran and n-heptane. The volume ratio between tetrahydrofuran and n-heptane can be between 1 :2 and 1 :3, preferably it is 1 :2.5. The concentration of compound of formula (4) in the mixture tetrahydrofuran and n-heptane can be between 0.1 g / ml and 0.16 g / ml. Compound of formula (4) is dissolved in the mixture tetrahydrofuran and n-heptane, preferably at a temperature between 50°C and 80°C, and the mixture is cooled to a temperature between 0°C and 25°C and preferably stirred at this temperature for between 5 and 60 minutes to obtain solid compound of formula (4).
[0082] Compound of formula (4) prepared according to presented invention contains less than 3% , preferably less than 2%, more preferably than 1% of Impurity (Imp) when measured by HPLC-UV method at 280 nm:
[0083] Cl O.
[0084] F?L
[0085] N
[0086]
[0087] (Imp)
[0088] Compound of formula (4) can be transformed into compound of formula (1) by a process described in the prior art or by a process comprising deprotecting the compound offormula (4) for example by using of an acid or by hydrogenation reaction. The acid can be selected for example from HC1 or HBr or H2SO4 or trifluoroacetic acid, preferably HC1, more preferably HC1 in aqueous solution is used. The reaction is done in a solvent, for example an alcohol such as methanol or ethanol. The concentration of compound of formula (4) in the solvent can be between 0.05 g / ml and 0.3 g / ml, preferably it is between 0.07 g / ml and 0.15 g / ml. Compound of formula (4) is mixed with the solvent and the mixture can be optionally cooled to a temperature between 0 and 20°C, preferably between 10°C and 18°C. To the mixture the acid is added. The molar ration between compound of formula (4) and the acid can be between 1 : 1.05 and 1:1.3, preferably it is between 1:1.1 and 1:1.2. The concentration of the acid in the solvent can be between 0.01 g / ml and 0.04 g / ml. The acid can be added in a single portion or in several portions, for example in 2 or 3 or 4 or 5 or 6 or 7 or 10 portions or drop-wise. After the acid is added, the mixture is stirred at the temperature between 0°C and 30°C for between 3 and 10 hours. The reaction progress can be monitored by a suitable analytical technique, e.g. by HPLC or GC. Optionally pH of the mixture can be set between 8 and 9, preferably to 8.5, for example by use of aqueous solution of a hydroxide such as sodium or potassium hydroxide. The mixture can be optionally treated with charcoal or cellite and filtered. Form the mixture or the filtrate used solvent is distilled of to remove between 40 vol% and 80 vol%, preferably between 50 vol% and 70 vol% of the solvent. The mixture is heated to a temperature between 50°C and 80°C. To the mixture an antisolvent (i.e. solvent where compound of formula (1) is poorly soluble) such as water is added. The volume ratio between added antisolvent and used solvent can be between 0.2:1 and 0.5:1. The antisolvent is added in a course between 15 and 120 minutes, preferably between 20 and 60 minutes. The mixture is stirred at a temperature between 50°C and 80°C for between 45 and 120 minutes. The mixture can be optionally cooled to a temperature between 0°C and 15°C and stirred at this temperature for between 2 and 10 hours to obtain a suspension. Obtained suspension isfiltered off and the filter cake can be washed for example with a mixture of methanol and water. Obtained solid can be optionally dried.
[0089] Compounds of formula (2) and (3) are either commercially available or can be prepared by a process described in prior art for example in WO2013171639.
[0090] The compound of formula (1) can be transformed into a salt or a co-crystal or a solvate thereof. The salt can be selected for example from HC1 or HBr or hydrogen sulfate or sulfate or an acetate or phosphate or maleate or citrate or mesylate (methane sulfonate) or esylate (ethane sulfonate) or tosylate (toluene sulfonate) or benzene sulfonate or nitrate or tartrate or gluconate or malate. The salt is preferably HC1.
[0091] The compound of formula (1) or a salt or a solvate or a cocrystal thereof can be processed into a suitable pharmaceutical formulation. In the pharmaceutical formulation the solid forms can be mixed with pharmaceutically acceptable adjuvants, diluents or carriers. The amount of solid compound of formula (1), in the formulation depends on the condition and a patient to be treated. The pharmaceutical formulation can be if form of a solid oral formulation, for example a capsule, a pill, a powder or a granule. In the solid oral formulation the compound of formula (1) can be mixed with one or more additives such as fillers or extenders or binders or wetting agents or disintegrating agents or absorbents or lubricants or buffering agents. The formulation in a form of a tablet or a dragee or a capsule or a pill or a granule can be coated with a coating or shell such as enteric or other coating. The oral formulation can be in a form of an oral emulsion or a solution or a suspension or a syrup. The formulation can contain suitable additives such as diluent(s) or wetting agent(s) or emulsifying agent(s) or suspending agent(s) or sweetening agent(s) or flavoring agent(s). The examples of suitable additive(s) are known to those skilled in the art.
[0092] The suitable pharmaceutical formulation can be in a parenteral form such as an injection or an infusion or an injectable depot or in a liposomal form comprising pharma-ceutically acceptable aqueous or non-aqueous solution(s) or dispersion(s) or emulsions. The pharmaceutical formulation can be also in a form of a powder for reconstitution into an injection or infusion. The formulation can further comprise additives such as preservative(s) or wetting agent(s) or emulsifying agent(s) or dispersing agent(s) or antibacterial or antifungal agents. The examples of suitable additive(s) are known to those skilled in the art.
[0093] The suitable pharmaceutical formulation can be in a form suitable for rectal or vaginal administration further comprising suitable additive(s). The examples of suitable additive(s) are known to those skilled in the art.
[0094] The compound of formula (1) or a salt or a solvate or a cocrystal thereof or a pharmaceutical formulation comprising it be used for the treatment of conditions treatable with compound of formula (1).
[0095] The invention will be further illustrated by the following examples.
[0096] EXAMPLES
[0097] The content of impurity (Imp) was measured by HPLC-UV method using following conditions:
[0098] Column: Arion Plus C18, 3.0 microns, 100 mm x 3.0 mm
[0099] Detection UV: 280 nm
[0100] Mobile phase A: acetonitrile
[0101] Mobile phase B: 0.1% formic acid
[0102] Flow: 0.6 ml / minGradient table:
[0103] Time MeOH CAN Water 0.1% FA Flow (min) (%) (%) (%) (%) (mL / min) Initial 0 15 0 85 0.600 1.00 0 15 0 85 0.600 5.00 0 90 0 10 0.600 10.00 0 90 0 10 0.600 11.00 0 15 0 85 0.600 15.00 0 15 0 85 0.600
[0104]
[0105] Example 1: Preparation of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide, compound of formula (4)
[0106]
[0107] 1 g of (R)-5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide and 0.9 g of l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole and 0.6 g of K2CO3 were dissolved in 7.04 g of tetrahydrofuran and 2 g of water. The mixture was degassed by applying 3 cycles of vacuum / argon. 6.2 mg of the catalyst was added and the mixture was heated to 75 °C. The mixture was stirred for 3 hours at 75°C and 0.3 g of l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole. The mixture was stirred at 75°C for 1 hour and analyzed with HPLC-UV method. The sample contained less than 0.1% of starting material of (R)-5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide and compound of formula (4) and impurity (Imp) in a ratio of 99.7:0.3 %LCin (280 nm):
[0108] .nOH
[0109]
[0110] (Imp)
[0111] Example 2: Preparation of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide, compound of formula (4)
[0112]
[0113] 1 g of (R)-5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide, 1.5 g of l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxa-borolan-2-yl)-lH-pyrazole, and 0.92 g of K3PO4 were dissolved in 7.04 g of tetrahydrofuran and 2 g of water. The mixture was degassed by applying 3 cycles of vacuum / argon. Then 6.2 mg of the catalyst was added and the mixture was heated to 75 °C and stirred at this temperature for 2 hours. The mixture was analyzed with HPLC-UV method. The ratio between compound of formula (4) and impurity (Imp) was 99.7:0.3 % LCin (280 nm).
[0114] Reaction mixture was diluted with 20 ml of isopropyl acetate and 10 ml of 5% aqueoussodium carbonate. The mixture was stirred for 20 minutes. Then the mixture was filtered, phases were separated, organic phase was washed with 10 ml of brine and concentrated in vacuo to dryness to give 1.8 g of compound of formula (4). Obtained compound of formula (4) was mixed with 4 ml of tetrahydrofurane and 10 ml of heptane. The mixture was heated to 70°C to obtain a solution and then cooled to 20°C to obtain a suspension. The suspension was filtered of to give 0.96 g of compound of formula (4) in yield 83% of theoretical yield in 98.9% LCin (280 nm) purity, containing 0.2% of impurity (Imp):
[0115]
[0116] (Imp)
[0117] Example 3: Preparation of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide, compound of formula (4)
[0118]
[0119] 1 g of (R)-5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide, 0.9 g of l-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole and 0.6 g of K2CO3 were dissolved in 7.04 g of tetrahydrofuran and 2 g of water. The mixture was degassed by applying 3 cycles of vacuum / argon. Then 8.5 mg of the catalyst was added and the mixture was heated to 75 °C and stirred at thistemperature for 30 minutes and analyzed with HPLC-UV method. The sample contained <0.1% of starting material (I), <0.1% of impurity (Imp) and 99.0% LCin (280 nm) of compound of formula (4):
[0120] mOH
[0121]
[0122] (Imp)
[0123] Example 4: Preparation of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide, compound of formula (4)
[0124]
[0125] Under argon atmosphere 50 g of (R)-5-bromo-N-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide, 60.1 g of l-(tetrahydro-2H-pyran-2-yl)-5-(4, 4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole, and 30 g of K2CO3 were mixed with 400 ml of tetrahydrofuran and 100 ml of water. Resulting suspension was degassed by applying three cycles of vacuum / argon refill. Then 367 mg of the catalyst was added and the mixture was heated to 65 °C. Stirring was continued for 1 hour and then the mixture was cooled to 25 °C. Celite and active charcoal were added and the reaction mixture was stirred for 1 hour. Then it was filtered through a pad of celite, the filter cake was washed with 50 ml of tetrahydrofuran. The phases were separated and organic phase was washed with 100 ml of5% aqueous sodium carbonate. Combined aqueous phases were back-extracted with 200 ml of ethyl acetate. Combined organic phases were washed with 100 ml of water followed by 50 ml of brine and concentrated in vacuo. The evaporation residue was dissolved in 360 ml of methanol at 65 °C. To the mixture 180 ml of water was added over 20 minutes. Resulting suspension was stirred at 65 °C for addition 40 minutes and then cooled to 7 °C and filtered. The filter cake was washed with 80 g of methanol / water mixture (2: 1 vol / vol) and dried at ambient temperature in vacuo to give 51.1 g (yield 89% of theoretical yield) of compound of formula (4) (99.9% purity containing <0.1% LCin (280 nm) of impurity (Imp)):
[0126]
[0127] (Imp)
[0128] Example 5: Preparation of Asciminib, compound of formula (1)
[0129]
[0130] 49.6 g of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide was suspended in 500 ml of methanol. The suspension was cooled to 15 °C with stirring. 11.13 g of 35% aqueous hydrochloric acid was added in a single portion and stirring at 15 °C was continued for 7 hours. To the mixture 10% aqueous sodium hydroxide was added to reach pH 8.5. Celite was added followed with active charcoal and the mixture was stirred at 23 °C for 30 minutes. Then it was filtered through a pad of celite, the pad was washed with 100 ml of methanol and the filtrate was partially concentrated in vacuo (45 °C, 300 mbar, 320 ml of distillate collected).The distillation residue was heated to 70 °C and 173 ml of water was added over 30 minutes while temperature of the reaction mixture was allowed to drop to 60 °C. Resulting suspension was stirred at 60 °C for 1 hour, then cooled down to 10 °C over 2.5 hours, stirred at 10 °C for additional 90 minute and filtered. The filter cake was washed with 80 ml of methanol / water 2:1 (v / v) mixture chilled to 10 °C. Obtained solid was dried (23 °C, 100 mbar) to give desired 37 g of Asciminib (yield 89% of theoretical yield) of 99.6% LCin (280 nm) purity.
[0131] Example 5: Preparation of Asciminib HC1 salt
[0132] 29 g of N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)-5-(lH-pyrazol5-yl)nicotinamide was mixed with 190 g of methanol and 7 g of 37% hydrochloric acid. The mixture is heated to 50 °C and the resulting solution was filtered. To the mixture 418 g of t-butyl methyl ether was added. To the mixture 0.26 g of N-(4-(Chlorodifluoro-methoxy) phenyl)-6-(3-hydroxypyrrolidin-l-yl)-5-(lH-pyrazol-5-yl)nicotinamide hydrochloride were added. The mixture was cooled to between 0°C and 5°C and stirred for 60 minutes to obtain a suspension. The suspension was filtered off and obtained solid was dried.
[0133] Comparative example 1: Preparation of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide, compound of formula (4) by use of process described in
[0134] WO20131711639
[0135]
[0136] 1 g of (7?)-5-bromo-7V-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide, 0.81 g of l-(tetrahydro-2J / -pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l / 7-pyrazole, and 1.42 g of K3PO4 were suspended in 10 g of toluene. The mixture was degassed by applying 3 cycles of vacuum / argon. Then 0.125 g of Pd(PPhs)4 was added and the mixture was degassed by applying one cycle of vacuum / argon. The mixture was stirred at 100 °C for 1 hour and analyzed after 1 hour with HPLC-UV method. The sample contained compound of formula (4) and impurity (Imp) in a ratio of 50.5:49.5 % LCin (280 nm):
[0137]
[0138] Comparative example 2: Preparation of N-(4-(chlorodifluoromethoxy)phenyl)-6-((R)-3-hydroxypyrrolidin-l-yl)-5-(l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5-yl)nicotinamide, compound of formula (4) by use of catalyst system described in
[0139] W02020230100
[0140]
[0141] 1 g of (7?)-5-bromo-7V-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide, 0.72 g of l-(tetrahydro-2J7-pyran-2-yl)-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-17 / -pyrazole, and 0.6 g of K2CO3 were suspended in 3.46 g of toluene and 2 g of water. The mixture was degassed by applying 3 cycles of vacuum / argon. Then 7 mg ofPd(dtbpf)C12 was added and the mixture was heated to 100 °C and stirred for 1 hour. It was analyzed with HPLC-UV method. The sample contained starting material (7?)-5-bromo-7V-(4-(chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-l-yl)nicotinamide, compound of formula (4), and impurity (Imp) in a ratio of 36:61:3 % LCin (280 nm). Analysis after additional 1 hour at 50 °C revealed no progress.
[0142] It can be concluded that when compound of formula (2) is reacted with compound of formula (3) in presence of catalyst according to the presented invention purity of obtained compound of formula (4) with respect to impurity (Imp) is improved:
[0143]
[0144] (Imp)
[0145] Example Impurity (Imp) in obtained mixture 1 0.3%
[0146] 2 0.2%
[0147] 3 <0.1%
[0148] 4 <0.1%
[0149] Comparative example 1 49.5%
[0150] Comparative example 2 3%
[0151]
Claims
CLAIMS1. A process for preparation of Asciminib, compound of formula (1), or a salt or a cocrystal or a solvate thereof:the process comprising:a. Reacting compound of formula (2) with compound of formula (3):Hal: halogen prot:Protectivegroup .in a presence of a catalyst selected froma compound of general formula Pd(Hah)2AriAr2Ari is imidazolidine or 2,3 -dihydro- IH-imidazole subtituted on N atoms with 1 or 2 An An is pyridine group that is subtituted with 1 or 2 Hah groupA is a phenyl group that can be substituted by 1 or 2 or 3 AlkiAlki is straight or branched alkyl group or alkyl aryl groupHah is selected from Cl or Brora compound of general formula Pd(Hah)(r|3-allyl)Ar5An is 2,3-dihydro-lH-imidazole subtituted on N atom with 1 or 2 AnAn is a phenyl group that can be substituted with 1 or 2 or 3 AlkiAlki is straight or branched alkyl group or alkyl aryl groupHah is selected from Cl or Brto provide compound of formula (4):b. Transforming compound of formula (4) into compound of formula (1) or a salt or a cocrystal or a solvate thereof.
2. The process according to claim 1 wherein the Hah group is Cl or Br.
3. The process according to claim 1 or 2 wherein Alki is selected from methyl or ethyl or propyl or isopropyl or butyl or isobutyl or heptyl or hexyl or 4-m ethyl heptyl or diphenyl methyl.
4. The process according to claim 3 wherein Alki is isopropyl.
5. The process according to any one of claims 1 to 4 wherein the catalyst is selected fromThe process according to claim 1 wherein the salt of compound (1) is selected from HC1 or HBr or hydrogen sulfate or sulfate or an acetate or phosphate or maleate or citrate or mesylate or esylate or tosylate or benzene sulfonate or nitrate or tartrate or gluconate or malate.
6. The process according to anyone of claims 1 to 6 wherein the Hal in compound (2) is selected from Cl or Br or I.
7. The process according to anyone of claims 1 to 6 wherein Prot in compound 3 is selected from tetrahydro-2H-pyran-yl or (benzyloxy) carbonyl (Cbz) or (tert-butoxy) carbonyl (Boc) or benzyl (Bz) or 4-methoxybenzyl (PMB) or ((2 -trimethyl silyl) ethoxy)-methyl.
8. The process according to anyone of claims 1 to 8 wherein the process is done in a presence of a base.
9. The process according to anyone of claim 1 to 9 wherein the reaction is done in a solvent selected from tetrahydrofuran or toluene or 2-methyl tetrahydrofuran or dioxane or dimethoxy ethane or water or a combination thereof10. The process according to any one of claims 1 to 10 wherein the compound of formula (4) comprises less than 2% of Impurity (Imp):(Imp) 11. The process according to claim 1 wherein step b. comprises deprotecting the compound of formula (4).
12. The process according to claim 14 wherein deprotecting is done by using an acid or by using hydrogenation reaction.
13. Compound of formula (4) comprising less than 2% of Impurity (Imp):(Imp) 14. Compound according to claim 14 comprising less than 1% of Impurity (Imp).
